Literature DB >> 28259917

USP39 promotes colorectal cancer growth and metastasis through the Wnt/β-catenin pathway.

Xianwen Yuan1, Xitai Sun1, Xiaolei Shi1, Hao Wang2, Guoyi Wu1, Chunping Jiang1, Decai Yu1, Weiwei Zhang1, Bin Xue3, Yitao Ding1.   

Abstract

In the present study, we first examined the expression of USP39 protein using tissue array containing 90 colorectal cancer (CRC) tissues and 9 clinical samples, and observed that it has significantly higher expression in cancer tissues as compared to the corresponding adjacent normal tissues. Also, we tested USP39 expression level in four CRC cancer cell lines and identified that it indeed had higher expression in all these CRC cell lines. In addition, its knockdown inhibited not only the cell growth of SW480 and HT29 cells, but also the cell migration and invasion. Further analysis of its molecular mechanism suggested that the expression of four crucial proteins of Wnt/β-catenin pathway, including β-catenin, TCF4, MMP2 and MMP9 was reduced as a result of USP39 knockdown. Taken together, all these findings demonstrated that USP39 protein plays an important role in the growth and metastasis of colorectal cancer mainly through Wnt/β-catenin pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28259917     DOI: 10.3892/or.2017.5454

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Ubiquitin-specific peptidase 39 regulates the process of proliferation and migration of human ovarian cancer via p53/p21 pathway and EMT.

Authors:  Congcong Yan; Jiahui Yuan; Jiajia Xu; Gongye Zhang; Xiaomei Li; Bing Zhang; Tianhui Hu; Xiaohua Huang; Yubin Mao; Gang Song
Journal:  Med Oncol       Date:  2019-10-21       Impact factor: 3.064

2.  USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Authors:  Zhenwang Zhang; Wu Liu; Xiajun Bao; Tian Sun; Jiawei Wang; Mengxi Li; Chao Liu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

3.  Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.

Authors:  Xi Tang; Lang Zha; Hui Li; Gang Liao; Zhen Huang; Xudong Peng; Ziwei Wang
Journal:  Oncol Rep       Date:  2017-08-25       Impact factor: 3.906

4.  miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer.

Authors:  Xiang Dong; Hailong Su; Feng Jiang; Haiyan Li; Guangwen Shi; Lijuan Fan
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

5.  USP39 regulates the cell cycle, survival, and growth of human leukemia cells.

Authors:  Chunxia Liu; Xiaojian Yao; Ming Li; Yaming Xi; Li Zhao
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

6.  miR-135 regulated breast cancer proliferation and epithelial-mesenchymal transition acts by the Wnt/β-catenin signaling pathway.

Authors:  Daqiong Jiang; Bo Zhou; Yan Xiong; Hongbing Cai
Journal:  Int J Mol Med       Date:  2019-01-29       Impact factor: 4.101

7.  Effects of miR‑106b‑3p on cell proliferation and epithelial‑mesenchymal transition, and targeting of ZNRF3 in esophageal squamous cell carcinoma.

Authors:  Guanen Qiao; Chenguang Dai; Yang He; Junjie Shi; Chunfang Xu
Journal:  Int J Mol Med       Date:  2019-02-25       Impact factor: 4.101

8.  RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation.

Authors:  Kaikai Ding; Jianxiong Ji; Xin Zhang; Bin Huang; Anjing Chen; Di Zhang; Xingang Li; Xinyu Wang; Jian Wang
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 9.867

9.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

Review 10.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.